// App-Quantinova.ai

: Full Benefit of Rivaroxaban Prophylaxis in High‐risk Ambulatory Cancer Patients: An Analysis of All Thromboembolic Events in CASSINI

Researchers

Presenter

  • A. Khorana

Principal Investigators

  • M. Streiff

  • M.G. McNamara

  • A.K. Kakkar

  • H. Riess

  • U. Vijapurkar

  • S. Kaul

  • P. Wildgoose

  • G. Soff

Medical Centers

  • Cleveland Clinic, Hematology Oncology, Cleveland, United States

  • Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, United States

  • Christie Hospital NHS Trust, Department of Medical Oncology, Manchester, United Kingdom

  • Thrombosis Research Institute and University College London, London, United Kingdom

  • Charite Univsmedizin Berlin, Berlin, Germany

  • Janssen Research & Development, LLC, United States

  • Janssen Scientific Affairs, LLC, Titusville, New Jersey, United States

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

Locations

  • United States

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Central Nervous System (CNS)

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

  • Oncology (ONC)

Disease

  • Myocardial infarction

  • Deep vein thrombosis

  • Pulmonary embolism

  • Venous thrombosis

  • Solid malignancies

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved